The Future of IgA Nephropathy Treatment
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.
Read More
Use of Povetacicept in Treatment of IgA Nephropathy
Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.
Clinical Trial Results From Emerging Therapies in IgA Nephropathy
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review clinical trials for new and emerging treatments for IgAN, highlighting atacicept and telitacicept.
Dual Inhibition of BlyS and APRIL in IgA Nephropathy
Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.
New Therapies in IgA Nephropathy
Brad Rovin, MD, outlines the use of complement inhibitors as an alternative to systemic glucocorticoids for the treatment of IgAN.
Interrupting Disease Progression of IgA Nephropathy
Experts in nephrology focus on the need for an agent which inhibits the pathogenesis or interrupts disease progression of IgAN.
Foundational Therapies in IgA Nephropathy
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, provide an overview of the foundational therapies approved for treatment of IgAN and their functions.
Disease Progression of IgA Nephropathy
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review the driving factors of disease progression of IgAN (immunoglobulin A nephropathy).
Clinical trial data on IgAN for therapies
Gerald B. Appel, MD, discusses the changing treatment landscape of IgAN.
Complement therapy in transplant patients in C3G
Anuja Java, MD, discusses the role of complement inhibitors in transplant patients with C3G.
Clinical trial data on complement inhibition in C3G
Carla M. Nester, MD, MSA, FASN discusses recent clinical trials on complement inhibitors for C3G.
Current standard of care for C3G
Carla M. Nester, MD, MSA, FASN discusses the current therapeutic area for C3G and what is on the horizon.
Barriers to kidney biopsy
Anuja Java, MD, discusses barriers to perform kidney biopsies to diagnose immune mediated kidney diseases in community settings.
Clues to C3G in a biopsy
Sanjeev Sethi, MD, discusses clues in the pathology of kidney biopsies that could lead to a C3G diagnosis.
Building expertise in C3G
A panel of glomerular disease specialists discuss the importance of building centers of excellence with expertise on the pathology of C3G.
Kidney biopsy C3G
Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in C3G.
Diagnosing C3G in pediatric patients
Carla M. Nester, MD, MSA, FASN, discusses the approach to diagnostic testing in pediatric patients suspected of C3G.
Diagnostic testing in C3G
Anuja Java, MD, discusses the diagnostic tests that could lead to a diagnosis of C3G.
Kidney biopsy as a guide for treatment and prognosis
Sanjeev Sethi, MD, and Gerald B. Appel, MD, discuss how the kidney biopsy can guide treatment and prognosis in IgAN.
The role of electro microscopy in the diagnosis of IgAN
Sanjeev Sethi, MD, discusses the role of the electro microscopy in IgAN.
The Pathology of IgAN on Kidney Biopsy
Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in IgAN.
Differential Diagnosis of C3G
Anuja Java, MD, discusses the differential diagnosis of C3G.
Consequences of a Late or Missed Diagnosis of C3G
Anuja Java, MD; Carla M. Nester, MD, MSA, FASN; and Gerald B. Appel, MD, discuss the consequences of a missed or late diagnosis of C3G.
Challenges of Managing C3G
Anuja Java, MD, and Gerald B. Appel, MD, discuss the challenges of managing C3G in their patients.
C3G in Pediatric Patients
Carla M. Nester, MD, MSA, FASN, discusses the differences of C3G in the pediatric versus adult population.
An Overview of C3G
Carla M. Nester, MD, MSA, FASN, gives an overview of C3G.
IgA Nephropathy in Pediatric Patients
Carla M. Nester, MD, MSA, FASN, discusses the challenges of IgAN in pediatric patients.
IgA Nephropathy in the Transplant Population
Anuja Java, MD, discusses the heterogeneity of disease activity and recurrence in IgAN transplant population.
IgA Nephropathy in Different Ethnic Populations
Gerald B. Appel, MD discusses the prevalence of IgAN in various populations and the heterogeneity of the disease.
An overview of IgA Nephropathy
A panel of glomerular disease specialists provide an overview of immunoglobulin A nephropathy (IgAN).